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Psoriasis is a multifactorial disease with a strong genetic background. It associates strongly to HLA-Cw0602. HLA-
C interacts with killer immunoglobulin-like receptors (KIR) on natural killer (NK) and some natural killer-T (NKT)
cells. KIR’s function is triggered by specific binding to HLA ligands, which depends on the amino acid 80 of the
MHC class I a-chain. This permits classifying all HLA-C alleles into two functional groups: asparagine (N80) or
lysine (K80) carrying alleles. Psoriasis patients recruited at disease onset were categorized as guttate, vulgaris
without arthropathy and vulgaris with arthropathy plus skin lesions. Patients and carefully matched controls were
genotyped for position 80 of HLA-C and for KIR. Based on possible HLA/KIR combinations, individuals were
classiﬁed according to expected NK/NKT cell responses: balanced (B), excess inhibition (EI), excess activation
(EA), or undetermined (U). HLA-Cw6 and position 80 genotyping associated strongly to disease, whereas KIR2DS1
associated weakly. Individuals of the U and EI classes were more common among guttate psoriasis patients, which
related to HLA-Cw0602 status. These results suggest that different levels for NK/NKT cell activation thresholds,
not only reduction, contribute to immune deregulation in psoriasis. In the guttate phenotype, balanced HLA-C/KIR
interactions might be altered by the presence of concomitant streptococcal infections.
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Psoriasis is a multifactorial skin disease with autoimmune
features that affects approximately 2% of the Caucasian
population. Psoriatic skin lesions appear as red scaly
plaques with an underlying inflammatory infiltrate involved
in both lesion initiation and maintenance (Hellgren, 1967).
Psoriasis vulgaris (PsV) is the most common clinical form of
the disease. It manifests with plaques located most often on
the scalp and extensor surfaces. Guttate psoriasis (PsG)
presents with acute and small drop-like lesions scattered
over the trunk, usually after an upper respiratory tract infec-
tion. A significant proportion of patients develop concurrent
arthritis (PsA), which is potentially incapacitating (Christop-
hers and Kiene, 1995; Asumalahti et al, 2002; Holm, 2005).
The cause of the disease and its subtypes is still un-
known, but several studies point to a strong genetic pre-
disposition interacting with triggering environmental factors.
The search for genetic determinants of psoriasis has been
intense, especially in the MHC region of chromosome
6p21.3 where the psoriasis susceptibility locus (PSORS)1
locus resides. This region is thought to harbor a major pso-
riasis gene(s) and has been thoroughly investigated (Ba-
lendran et al, 1999; Oka et al, 1999; Nair et al, 2000). Several
PSORS1 candidate genes were proposed and tested in
association studies (STG, CDSN, PSORS1C1-3, HCR,
TCF19, POU5F1, HLA-C) (Jenisch et al, 1999; Enerback
et al, 2000; Gonzalez et al, 2000; Teraoka et al, 2000;
O’Brien et al, 2001; Asumalahti et al, 2002; Chang et al,
2003; Holm et al, 2003; Sanchez et al, 2004; Carlen et al,
2005). The earliest association reported in psoriasis for any
of these candidate genes was to HLA-C (McMichael et al,
1978). Even though HLA-Cw0602, an allele of the HLA-C
gene, remains the factor with the strongest association to
psoriasis, its role is disputed with arguments such as: not all
HLA-Cw0602-positive individuals develop psoriasis, more
than 30% of psoriasis patients are HLA-Cw0602 negative,
haplotypes carrying HLA-Cw0602 associate more strongly
to psoriasis than the allele itself, and other candidate var-
iants reach the same level of association as HLA-Cw0602
(Trembath et al, 1997; Jenisch et al, 1999; Asumalahti et al,
2000; Nair et al, 2000; Allen et al, 2001; Chia et al, 2001;
Asumalahti et al, 2002). These arguments are, however,
based on methods that bear the expectation of simple
Mendelian inheritance patterns, which in the case of the
PSORS1 locus, are unlikely to accommodate for the likely
effect of other candidate genes in the region and of genes in
other genomic locations (PSORS2–PSORS9) (Wain et al,
2004). Psoriasis is a multifactorial disease and, as such,
HLA-C cannot be disregarded simply because of non-Men-
delian behavior. HLA-Cw0602 is indeed present in about
60% of the psoriasis patients compared with 10% of the
controls in the Swedish population (Enerback et al, 1997).
Abbreviations: B, balanced; CI, confidence interval; EA, excess
activation; EI, excess inhibition; K, lysine; KIR, killer immunoglob-
ulin-like receptor; MIC, MHC class I chain-related; N, asparagine;
NK, natural killer; NKT, natural killer-T; PsA, psoriasis arthritis; PsG,
guttate psoriasis; PsV, psoriasis vulgaris; OR, odds ratio; PSORS,
psoriasis susceptibility locus; U, undetermined
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Relative to other PSORS1 candidates, HLA-Cw0602 con-
sistently shows the strongest association to disease in var-
ious populations, (Economidou, 1985; Nakagawa et al,
1991; Enerback et al, 2000; O’Brien et al, 2001; Asumalahti
et al, 2002; Kundakci, 2002; Tsai et al, 2002; Holm et al,
2003). Furthermore, homozygotes for this allele appear to
have a higher risk of developing psoriasis than heterozy-
gotes (Gudjonsson et al, 2003). In addition, altered immune
responses seem to be central to psoriasis pathogenesis,
which provides a ground for studying HLA-C’s involvement
in this phenotype. The contribution of HLA-C to psoriasis
should be studied from the perspective that its effect is
important but partial, it associates more with some clinical
features (young age, PsG), and that it might interact with
other candidate genes in this and/or other regions.
HLA-C is recognized by natural killer and natural killer-T
(NK/NKT) cells through the killer immunoglobulin-like re-
ceptors (KIR) (Colonna et al, 1993; Mandelboim et al, 1996;
Winter et al, 1998). These and other NK/NKT cell receptors
enable the immune system to assess the type and level of
HLA class I expression on target cells (Algarra et al, 2004).
Cells with altered HLA class I expression induce NK/NKT
cell activation (Bottino et al, 2004). Miscommunication be-
tween HLA-C and KIR is likely to initiate inappropriate im-
mune responses. Interestingly, the number of circulating
NK/NKTcells appears to be reduced in psoriasis, as in other
autoimmune disorders, suggesting a pathogenic role for
these cells (Cameron et al, 2002). In fact, NK/NKT cells, a
subpopulation of T cells that also carry KIR, are found in
chronic psoriatic plaques and are known to induce similar
lesions in severe combined immunodeficient (SCID) mice
(Nickoloff, 1999; Bonish et al, 2000; Gilhar et al, 2002). In
addition, recent data show that activated T cells are re-
quired for development of psoriatic lesions in K5.Stat3C
mice (Sano et al, 2005).
So far, the KIR locus on chromosome 19q13.4 is known
to contain 16 KIR genes and pseudogenes (Hubbard et al,
2002). KIR are activating or inhibitory depending on their
structure. The activating receptors carry a short (S) cyto-
plasmic tail and the inhibitory receptors carry a long (L) cy-
toplasmic tail. Upon engagement by MHC class I molecules,
KIR(L) regulate NK/NKT cell cytotoxicity by antagonizing the
activating signals from KIR(S)-activating receptors (Bottino
et al, 2004). KIR are able to distinguish between different
HLA-A, B, and C allotypes according to the allelic residue at
position 80 of the MHC class I a1 helix. Group 2 HLA-C
alleles carrying a lysine (K80) at this position (HLA-Cw2, 4, 5,
6, and 15) are recognized by KIR2DL1, and KIR2DS1. Group
1 alleles, carrying an asparagine (N80), are recognized by
KIR2DL2 and KIR2DS2 (HLA-Cw1, 3, 7, and 8) (Mandelboim
et al, 1996; Winter and Long 1997; Boyington et al, 2001).
Since the number of genes at the KIR locus varies between
individuals from 7 to 14 genes (Uhrberg et al, 1997), and
since the MHC and KIR loci reside on different chromo-
somes, individuals can inherit both the ligand and the re-
ceptor, only the ligand, or only receptor. These HLA/KIR
combinations could thereby lead to differences in NK/NKT
cell activation thresholds. Recent studies show the associ-
ation of KIR2DS1 to psoriasis vulgaris (Luszczek et al, 2004;
Suzuki et al, 2004), and of KIR2DS1 and KIR2DS2 to pso-
riasis arthritis (Hewett et al, 2002; Nelson et al, 2004).
The frequency distributions for the various HLA/KIR
combinations among patients with PsG, PsV, and PsA were
compared with those found in the control group. All indi-
viduals were classified according to the expected net bio-
logical effect for such combinations. Significantly less PsG
individuals were classified as having undetermined (U) HLA-
C/KIR combinations. Also, among these patients there were
more individuals classified as having an increased potential
for NK/NKTcell inhibition. A trend for increased potential for
activation was found among PsA patients.
Results
The distributions of genotypes for HLA-Cw0602, KIR2DL1,
KIR2DL2, KIR2DS1, KIR2DS2, and KIR2DS4 in 396 psoria-
tic patients and 372 matched controls were identified. Gen-
otypes for the codons 73, 77, and 80 of the HLA-C gene,
and combinations of codon 80 variants with their function-
ally related KIR genes were also studied.
All patients and controls were recruited from the Stock-
holm area, and had similar gender and age distributions.
But age differences were detected between phenotypes.
PsG patients were significantly younger (mean¼32.8 y)
than vulgaris (mean¼ 42.3 y) and psoriasis arthritis patients
(mean¼ 45.8 y) (p¼106). Proportions of males and fe-
males were comparable across phenotypes and among
controls, although a trend for more women in the arthritis
group was observed.
HLA-C typing
HLA-Cw0602 association to psoriasis varied depending
on phenotype The background level of HLA-Cw0602
positivity in our sample was 10.5%. Patients carried this
allele in a significantly higher proportion (38%, odds ratio
(OR)¼5.23, confidence interval (CI) [3.54–7.73], p¼ 4.07
 1019) but the differences were more pronounced for pa-
tients classified within certain phenotypes (Table I). Re-
markably, HLA-Cw0602 was found in 73% of guttate
patients (OR¼ 22.70, CI [12.44–41.42], p¼ 2.69  1028).
Genotypes at codon positions 73, 77, and 80, as deter-
mined by pyrosequencing, were found to be at expected
frequencies in the control population. Positions 77 and 80
were in linkage disequilibrium (D0 ¼ 0.95, CI [0.91–0, 97],
r2¼ 0.69), whereas position 73 appeared to segregate in-
dependently. Position 73 was associated with PsV diag-
noses, whereas it showed an inversed pattern of
association to PsA (Table II). Genotypes at position 77 and
position 80 were significantly associated with disease sta-
tus. There was similar risk for position 77 heterozygote and
TT homozygote PsG individuals (OR¼12.6 vs OR¼11.1),
whereas association to either genotype was much lower for
PsA and PsV (Table II). Position 80 TT individuals were sig-
nificantly more common among PsG individuals but the
level of association to psoriasis was about three times lower
than that for the heterozygote genotype (OR¼3.9 vs
OR¼13.1).
Estimated haplotypes between positions 77 and 80 oc-
curred at the following frequencies: 7.3% for 77C–80T,
39.5% for 77T–80T, and 52.5% for 77C–80G. Haplotypes
77C-80T and 77T-80T were significantly associated with
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psoriasis (w2¼15.86 p¼6.82  105, and w2¼7.67
p¼0.0056, respectively).
KIR2DS1 associates to PsV The proportion of individuals
with activating KIR2DS1 receptors was significantly higher
among patients than controls (OR¼ 1.47, CI [1.10–1.96],
p¼0.010), particularly in PsV patients (OR¼ 1.48, CI [1.06–
2.05], p¼ 0.023). There was also a trend towards a higher
KIR2DS1 frequency among PsA patients (Table III). The
other KIR receptors considered here did not associate to
disease.
The most common KIR combinations found in this ma-
terial are presented in Table IV. None of them associated
with disease status.
PsG patients differed from other phenotypes when clas-
siﬁed according to functional expectations for HLA-C
position 80/KIR genotype combinations The proportions
of individuals in the balanced (B)-, excess inhibition (EI)- or
excess activation (EA)-predicted ‘‘functional’’ classes were
similar between controls and patients as a whole. Individ-
uals within the EA class were under-represented among
patients and controls in general and across phenotypes,
although there was an increased proportion of EA individ-
uals among PsA patients (4% vs 1.2%, w2¼ 1.67, DF¼1,
P¼NS) (Fig 1).
PsG patients showed a distinctive profile compared with
the other phenotype groups (w2¼22.14, DF¼ 9, p¼0.01).
They had similar proportions of B and EA individuals as
controls, more EI individuals (47.44% vs 31.93%, w2¼ 6.4,
DF¼ 1, pcorrected¼0.048), and significantly less individuals
of the U class (3.85%, vs 21.01% w2¼ 12.81, DF¼1,
pcorrected¼0.0004). The proportion of individuals classified
as having potentially balanced NK/NKT cell responses was
similar between all groups, but about one-third of the gutt-
ate patients with this profile had a concomitant strepto-
coccal throat infection at psoriasis onset (data not shown).
Individuals carrying HLA-Cw0602 were more likely to be
classified as EI, whereas most U individuals lacked this
allele (Fig 2).
When stratifying patients according to age of disease
onset into type I or type II, no differences in HLA-C/KIR
distributions were observed (data not shown).
Discussion
In this study, the relationship of HLA-C with psoriasis was
explored from the perspective of gene–gene interaction.
Accordingly, the KIR locus was considered the primary in-
teracting partner to HLA-C. The basis for this was the
emerging concept that HLA-C/KIR molecular interactions
depend on a limited number of conditions: the amino acid
Table I. HLA-Cw0602 association to psoriasis according to phenotype
Category Frequency OR (CI) p-valuea
Guttate 72.73% (56/77) 22.70 (12.44–41.42) 2.69  1028
PsA 24.62% (16/65) 2.78 (1.44–5.35) 0.0037
Vulgaris 30.54% (73/239) 3.74 (2.43–5.76) 4.58  107
Patients total 38.06% (145/381) 5.23 (3.54–7.73) 4.07  1019
Controls 10.51% (39/371) — —
aDetermined by Fisher’s exact test.
OR, odds ratio; CI, confidence interval; PsA, psoriasis arthritis.
Table II. Odds ratios (OR), conﬁdence intervals (CI), and p-values for the frequencies of variants at codon position 73, 77, and 80 of
HLA-C in different psoriasis phenotypes
Position
Guttate PsA PsV All phenotypes
OR (CI) pc-value
a OR (CI) pc-value
a OR (CI) pc-value
a OR (CI) pc-value
a
73
CC 1.29 (0.49–3.44) NS 0.55 (0.27–1.10) NS 2.23 (1.35–3.85) 0.009 1.43 (0.92–2.23) NS
CT 2.52 (1.08–6.07) NS 0.44 (0.23–0.85) 0.042 1.21 (0.70–2.07) NS 1.08 (0.70–1.65) NS
77
CT 12.2 (3.57–50.14) 6  108 0.69 (0.36–1.32) NS 1.29 (0.86–1.93) NS 1.50 (1.05–2.14) NS
TT 12.3 (4.46–39.18) 6.7  106 1.91 (0.97–3.76) NS 1.94 (0.87–2.40) NS 1.94 (1.25–3.00) 0.01
80
GT 14.2 (5.37–41.34) 0.002 1.21 (0.69–2.14) NS 1.94 (1.31–2.89) 0.003 2.31 (1.65–3.25) 1.2  105
TT 11.7 (2.65–14.12) 0.039 0.73 (0.30–1.71) NS 1.85 (1.12–3.06) 0.045 1.7 (1.10–2.68) 0.031
aDetermined by Fisher’s exact test.
pc, corrected p value; PsV, psoriasis vulgaris; PsA, psoriasis arthritis; NS, not significant.
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present at position 80 of HLA-C (which defines the subset of
KIR that can bind to this protein), the expression of specific
KIR genes, the number of HLA class I molecules expressed
on target cells, and the expression of other NK/NKT cell
receptors able to sense HLA levels (Mandelboim et al, 1996;
Uhrberg et al, 1997; Winter et al, 1998; Boyington and Sun,
2002; Bottino et al, 2004). An arbitrary classification of study
individuals into potential ‘‘functional’’ classes was estab-
lished. Four classes were defined as representing the likely
functional outcome of HLA-C/KIR interactions, assuming
expression of all alleles involved and no interference from
other gene products (Table V). These classes were com-
pared between patients and controls under the hypothesis
that, if interactions between these two molecules were rel-
evant to psoriasis, a non-random distribution of response
profiles would be found.
The main effects of HLA-Cw0602 and of the KIR genes
considered in this study agreed with association measure-
ments reported previously in different studies (Enerback
et al, 2000; O’Brien et al, 2001; Asumalahti et al, 2002; Holm
et al, 2003). HLA-Cw0602 strongly associated to psoriasis,
especially to PsG. Significant association was also ob-
served for early-onset psoriasis (o25 y of age), which cor-
related with a large proportion of PsG individuals of young
age at disease onset (data not shown) (Enerback et al, 1997;
Mallon, 2000; Gudjonsson et al, 2002). Genotypes at posi-
tions 77 and 80 also associated strongly to psoriasis, fol-
lowing the same pattern as HLA-Cw0602 in relation to
phenotype and age of onset. In contrast, position 73 was
only slightly associated with PsG and PsA diagnoses,
whereas it showed an inverse pattern of association to PsV.
In this study, KIR2DS1 associated significantly to pso-
riasis, particularly to PsV, and showed a trend in PsA. Pre-
vious studies report excess of individuals with activating
receptors that lack a ligand for the corresponding inhibitory
receptor among PsV patients (Luszczek et al, 2004; Suzuki
et al, 2004) and among PsA patients (Hewett et al, 2002).
These findings support the concept that inadequate control
of NK/NKT cell activation contributes to psoriasis patho-
genesis.
A number of studies report that particular HLA Class I/
KIR combinations contribute to disease. For example, HIV
infection in people carrying HLA-Bw4-80Ile and KIR3DS1
progresses slower to AIDS; type I diabetes patients more
often carry KIR2DS2 and its ligand HLA-C-Asn80, which RA
patients with vasculitis also carry, in the absence of the
corresponding inhibitory receptor (Venter et al, 2001; Hewett
et al, 2002; van der Slik et al, 2003). These studies focused
on determining the proportions of individuals carrying cer-
tain KIR in the presence or absence of particular ligand HLA
class I molecules. Using a more robust approach, this study
predicted the likely biological effects of HLA/KIR combina-
tions based on limited assumptions, and classified study
individuals accordingly. This method revealed that individ-
uals within the EA class, i.e., individuals with HLA-C/KIR
combinations favoring NK/NKT cell activation, were a mi-
nority among patients as well as controls. A trend for higher
proportions among PsA individuals, however, was also
found. This result along with previous indications that in-
hibitory receptors have higher affinity for their ligand than
activating receptors (Winter et al, 1998), and that placental
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inhibition of NK/NKT cell activation is crucial during preg-
nancy (Hiby et al, 2004) suggest that profiles favoring lower
NK/NKT cell activation thresholds would be maintained at
low frequencies in populations. Activation in this system
occurs naturally when HLA-C expression is reduced, which
is a common feature in viral infections and cancer. But, in
theory, direct engagement of activating KIR or manipulation
of their signalling pathways by infectious agents could lead
to disease. This study also found that PsG had a singular
predicted responsiveness profile. Among these patients,
there was a higher proportion of EI, and a reduced propor-
tion of U profiles. Individuals of the EA class were more
common among PsA patients, which is in agreement with
the findings reported above in relation to KIR2DS1. A large
proportion of HLA-Cw0602-positive EI class PsG individ-
uals was found, whereas this allele was significantly un-
common among U class individuals. Additionally, PsG
patients belonging to class B more often reported a con-
comitant throat infection at disease onset, confirmed as
streptococcal by swab tests.
These findings suggest that inadequate communication
between HLA-C and KIR contributes to psoriasis patho-
genesis and that HLA-Cw0602 is an important player, es-
pecially in PsG and likely in relation to streptococcal
infection in young individuals (Enerback et al, 1997; Allen
et al, 2005). Since the NK/NKT cell response profiles found
in this population were robustly defined by zygosity at po-
sition 80 regardless of the HLA-C alleles present, contribu-
tion by alleles other than HLA-Cw0602 is expected.
Studies that report weak association to HLA-Cw6 might
benefit from incorporating KIR into their analyses, thus ac-
counting for the effect of other HLA-C alleles. It seems in-
tuitive that lower NK/NKT cell activation thresholds
contribute to pathogenesis (Hewett et al, 2002); in contrast,
our finding that more PsG patients fell into the EI class is
somewhat intriguing in relation to psoriasis pathogenesis.
Figure 1
Distribution of predicted functional classes among guttate psoriasis (PsG), psoriasis arthritis (PsA), and psoriasis vulgaris (PsV) patients
and among controls. HLA-C/KIR genotype combinations according to phenotype.
Table IV. Distribution of KIR combinations in patients and controls (n)
KIRa Control Guttate PsA Vulgaris Patients total
PNNN 112 16 16 64 96
PNPN 68 15 18 49 82
PPNP 82 21 15 41 77
PPPP 72 19 18 57 94
aThe KIR genes are presented in following order: 2DL1, 2DL2, 2DS1, and 2DS2.
KIR, killer immunoglobulin-like receptor; P, present; N, absent; PsA, psoriasis arthritis.
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Does the contribution of this profile to psoriasis result from a
reduced ability to overcome inhibition when activation is
required? Does it result from a direct pathogenic effect of
the inhibitory process? Also intriguing was the presence of
similar proportions of B class individuals across phenotypes
and in controls. There might be different ways to produce
imbalance in the NK/NKT cell activation process. It is pos-
sible that this system is a target for different triggering fac-
tors, such as infection (streptococcus, staphylococcus,
other), pharmaceuticals, immunomodulatory molecules,
etc. During infection for example, the lack of NK/NKT cell
responsiveness could be advantageous to the agent in
ways that favor psoriasis development as a by-product of
immune deregulation. In this regard, it is important to men-
tion that bias towards TH1 responsiveness is a hallmark of
psoriasis, and that NK/NKT cells observed in this disease
(Nickoloff, 1999; Bonish et al, 2000; Cameron et al, 2002)
could be a source of TH1cytokines. A TH1-like cytokine se-
cretion pattern (IFN-g, TNF-a, and IL-6) was reported for
NK/NKT cells upon engagement of activating receptors by
HLA-C (Barakonyi et al, 2004). The fact that infections might
trigger disease development does not imply that psoriasis
patients are more susceptible to infection. It may suggest
that individuals with inherently frail NK/NKT cell regulation
are more prone to psoriasis. Remarkably, a third of the
guttate patients with predicted balanced responses in this
study had a concomitant streptococcal throat infection,
suggesting that this factor might take them off balance,
whereas it might further contribute to already imbalanced
HLA-C/KIR interactions in other patients. Since our patients
and controls are being prospectively followed, it is of
interest to determine whether worsening of symptoms in
patients or occurrence of psoriasis among controls corre-
lates with the external triggers that are being considered in
this cohort.
It is not clear as to what is responsible for the NK/NKT
cell imbalance in U class individuals; however, cross-reac-
tivity between KIR and HLA-C groups has been described.
The model proposed here is assumed to be incomplete
since it does not consider other known interacting partners.
It is likely that other receptors and their ligands need to be
included into the analysis before a more complete picture of
the decision-making process leading to NK/NKT cell acti-
vation in psoriasis is developed. Since the HLA/NK cell re-
ceptor system senses quantitative differences in HLA class I
expression, it is crucial to determine whether expression of
both receptors and ligands (e.g., HLA-E) occur at propor-
tions corresponding to the ones expected from the geno-
typic patterns. In other words, to study whether the
potential NK/NKT cell responses in a given individual de-
pend on an expression threshold. It is possible that differ-
ential allelic expression contributes to fine tuning the events
leading to NK/NKT cell activation. Therefore, determining
allelic expression at the RNA as well as the protein levels is
essential in understanding the events involved in this inter-
action. Also environmental triggers that might bypass or
modify HLA/KIR signalling, in favor of activation or inhibition
under different pathological contexts, need to be deter-
mined.
The KIR locus was investigated in this study because
these receptors are known functional interacting partners of
HLA-C molecules. Indeed, an association between HLA-C/
Figure 2
Distribution of proportions of HLA/KIR (killer immunoglobulin-like receptor) combinations in patients with guttate, vulgaris, and arthritis
psoriasis and controls divided by HLA-Cw0602 status (N, negative, P, positive). HLA-C/KIR genotype combinations according to phenotype and
HLA-Cw6 status.
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KIR combinations and psoriasis was found, supporting an
immunity-based theory of psoriasis. This provides the pos-
sibility that other proteins known to be active in the immune
system can be included in the model. An important as-
sumption of such a broad model is that molecular interac-
tions occurring in multiple ways may lead to disease
outcome. This open model, more akin to observed biolog-
ical networks, allows for the inclusion of other members of
the PSORS1 region. For example, MIC molecules have
previously been shown to associate with psoriasis. These
molecules are in fact recognized by NK/NKT cells as their
expression seems to be triggered by low levels of HLA class
I expression (Cheng et al, 2000; Dunn et al, 2000). It will
therefore be important to determine whether HLA-C and
MIC, and perhaps other immune molecules interact in pso-
riasis pathogenesis.
Materials and Methods
Study population A total of 396 psoriasis patients and 372 con-
trols were investigated in this study. The patients were recruited
within 1 y of disease onset. Each patient was thoroughly examined
by a dermatologist. Whenever psoriasis arthropathy was suspect-
ed, a rheumatologist assessed clinical features to ensure diagno-
sis. PsV without joint symptoms was diagnosed in 241 patients,
PsG for 80 patients, and PsV with concomitant arthropathy in 75. A
few patients manifested mild joint symptoms but a clear acute
onset of guttate lesions. They were classified within the guttate
category for the present analysis purposes. The characteristics of
the majority of patients are described in detail elsewhere (Mallbris,
2005). The mean age of onset was 41 y (females 41.85, males
39.78), with a range between 12 and 84 (females 12–84, men 13–
80). The controls consisted of 214 females and 158 males and
were selected from the Stockholm County as random samples by
means of the population register, taking age, sex, and living district
into consideration. Informed consent was given by all study par-
ticipants. This study fulfilled the requirements of the Regional
ethics Committee of Stockholm, Sweden, and was performed ac-
cording to the Declaration of Helsinki.
Bioinformatics To ensure proper positioning of the primers used
in this study, all known alleles of HLA-C and KIR were considered
for sequence analysis (Bunce et al, 1995; Hewett et al, 2002; et-
okebe et al, 2003). Publicly available sequences for HLA-C and KIR
(Robinson et al, 2005) were imported and assembled using the
Pregap4 and Gap4 programs of the Staden package (Bonfield
et al, 1998) and compared with each other. All primer sequences
designed were compared with the human genome using BLAST. In
addition, primers designed for HLA-C-related amplifications and
sequencing were compared with SNP and STS databases to
search for unknown SNP that could affect primer binding and am-
plification in this very polymorphic region.
HLA-Cw0602 and KIR genotyping Genomic DNA was extracted
from all individuals using standard conditions (Sambrook et al,
1989). For the detection of products from the KIR2DL1, KIR2DS1,
TableV. Primers used for the ampliﬁcation of HLA and KIR, expected amplicon size and annealing temperature
Primer Sequence Size (bp) Temp (1C)
Phototyping
HLA-Cw6 (127) 50-GGT CGC AGC CAT ACA TCC A-30 297 65
HLA-Cw6 (367) 50-TAC TAC AAC CAG AGC GAG GA-30
DRB1 Fa 50-TGC CAA GTG GAG CAC CCA A-30 796 —
DRB1 Ra 50-GCA TCT TGC TCT GTG CAG AT-30
KIR2DL1F 50-TGG ACC AAG AGT CTG CAG GA-30 330 63
KIR2DL1R 50-TGT TGT CTC CCT AGA AGA CG-30
KIR2DL2F 50-CTG GCC CAC CCA GGT CG-30 173 62
KIR2DL2R 50-GGA CCG ATG GAG AAG TTG GCT-30
KIR2DS1F1 50-CTT CTC CAT CAG TCG CAT GAA-30 102 64
KIR2DS1F2 50-CTT CTC CAT CAG TCG CAT GAG-30
KIR2DS1R 50-AGA GGG TCA CTG GGA GCT GAC-30
KIR2DS2F 50-TTC TGC ACA GAG AGG GGA AGT A-30 173 63
KIR2DS2R 50-AGG TCA CTG GGA GCT GAC AA-30
Pyrosequencing
HLA-C.F 50-AGCGAGGKGCCCGCCCGGCGA-30 918 67
HLA-C.R 50-GGAGATGGGGAAGGCTCCCCACT-30
HLA-C.FN 50-NNNNNNNNNCCCGCCCGGCddG-30 919 67
HLA-C.RN 50-NNNNNNNNNNAAGGCTCCCCddA-30
Pos80.F 50-(Biotin)TCGACAGCGACGCCGCGAGTCC-30 162 65
Pos80.R 50-CCTCCGCTCTGGTTGTAGTAGCCGCG-30
aInternal control included in all reactions but for pyrosequencing. Primers are specific for a 796 bp amplicon from the third exon of DRB1.
KIR, killer immunoglobulin-like receptor; N, asparigine.
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KIR2DL2, and KIR2DS2 genes, previously published primer se-
quences were used (Hewett et al, 2002) (Table VI). Amplification
was performed under standard conditions using Taq polymerase
(Promega, Madison, Wisconsin) in a PTC-225 DNA Engine Tetrad
(MJ Research, Waltham, Massachusetts). Briefly, 50–100 ng gen-
omic DNA was used as a template in 10 mL PCR mixtures con-
taining 100 nM of each specific primer, 50 mM of each internal
control primer, 2 mM dNTP, 0.95% DMSO, 0.5 U of Taq polym-
erase, 67 mM Tris-HCl pH 8.8, 16 mM (NH4)2SO4, 2.5 mM MgCl2,
0.01% Tween-20, 0.1 mg per mL BSA. Temperature cycling con-
sisted of the following: denaturation at 951C for 2 min, five cycles of
20 s at 941C, 30 s at 681C, and 80 s at 721C, followed by 30 cycles
of 20 s at 941C, 30 s at 621C–651C (Table VI), and 80 s at 721C and
a final elongation step at 721C for 5 min. HLA-Cw0602 status was
determined as described previously (Bunce et al, 1995). Resulting
products of predicted size were visualized under ultraviolet light
after electrophoresis in 1.5% agarose gels containing ethidium
bromide.
Pyrosequencing for HLA-C variants Genotyping of identified
SNP specific for the three codons determining amino acids 73, 77,
and 80 of HLA-C was carried out through Pyrosequencing in a 96-
well format, according to the supplier’s recommendations (Pyr-
osequencing, Uppsala, Sweden). HLA-C-specific amplicons were
produced by a nested amplification protocol. First, an outer PCR
using HLA-C-specific primers (HLA-CF, HLA-CR) was performed.
To block amplification from closely related sequences this reaction
was carried out in the presence of competitor primers (degener-
ated and dideoxy capped oligos, HLA-CFN, and HLA-CFR) (Et-
okebe et al, 2003) (Table VI). Temperature cycling conditions
consisted of: 35 cycles of 20 s at 951C, 60 s at 671C, and 120 s at
721C, followed by a final elongation step of 8 min at 721C. These
products were used as template for a nested PCR using primers
pos80.F and pos80.R (Table VI). These primers were designed to
recognize homologous sequences on most alleles. Care was taken
to avoid polymorphic places that could bias amplification reac-
tions. Temperature cycling conditions for the nested PCR were as
follows: denaturation at 961C for 1 min, five cycles of 25 s at 961C,
45 s at 701C, and 45 s at 721C, followed by 21 cycles of 25 s at
961C, 50 s at 651C, and 45 s at 721C, and an additional 11 cycles of
25 s at 961C, 60 s at 551C, and 120 s at 721C. The forward primer
was biotinylated at the 50 end to allow capture using streptavidin-
coated magnetic beads (Dynal Biotech, Oslo, Norway). Captured
products were denatured, and the remaining single strands were
annealed to the sequencing primer (pos80.R) (Table VI). Se-
quencing was performed on a PSQ96 Pyrosequencer using the
reaction mixtures provided by the supplier (Pyrosequencing, Upp-
sala, Sweden). Reactions were followed in real time as luminous
signals generated during nucleotide polymerization. These signals
were automatically converted to genotypes by the PSQ HS96A 1.2
software. Data quality control was performed by direct inspection
against all possible patterns expected for the three contiguous
variations targeted in this study.
Classiﬁcation of HLA-C/KIR combinations according to ex-
pected effects Activating and inhibitory KIR initiate their corre-
sponding signalling cascades after binding to their specific ligands.
For each ligand group, there is a corresponding set of one acti-
vating and one inhibitory receptor; group 2 (K80) alleles interact
with KIR2DL1 and KIR2DS1, and group 1 (N80) with KIR2DL2 and
KIR2DS2. In human populations, however, there are different pro-
portions of individuals who carry ligand and receptor simultane-
ously, some ligand only and some receptor only. The predicted
biological outcomes from these situations were defined in this pa-
per as follows: B, if both inhibitory and activating HLA/KIR com-
binations for either or both ligand group(s) were present
simultaneously; EI, if one or two inhibitory HLA/KIR combinations
were present but activating HLA/KIR combinations were in minority
or missing; EA, if one or two activating HLA/KIR combinations were
present but inhibitory HLA/KIR combinations were in minority or
missing; and undetermined (U) when no matching HLA/KIR com-
binations were detected (Table II). All combinations were based on
zygosity information from position 80.
Statistics Hardy–Weinberg (HW) equilibrium and linkage disequi-
librium (LD) tests were performed using the R language and pro-
gram for statistical computing (Ihaka and Gentleman, 1996).
Comparisons of proportions are presented with their correspond-
ing OR and 95% CI. Their significance values were determined by
Fisher’s exact test. A significance level a¼ 0.05 was the reference
for most comparisons. Bonferroni correction was used to define
significance levels when indicated. Haplotype estimation was per-
formed using the partition/ligation method implemented in Haplo-
view (Barrett et al, 2005).
TableVI. Classiﬁcation scheme of HLA-C/KIR genotype combinations and their potential NK cell response
HLA-C position 80 amino acid Corresponding KIR
HLA-C position 80 amino acid
K (lysine) N (asparagine)
L1/S1 L1/00 00/S1 00/00 L2/S2 L2/00 00/S2 00/00
K (lysine) L1/S1 B
L1/00 B EI
00/S1 B B EA
00/00 B EI EA U
N (asparagine) L2/S2 B EI EA B B
L2/00 EI EI B EI B EI
00/S2 EA B EA EA B B EA
00/00 B EI EA U B EI EA U
The genotyping corresponding to the amino acid present at position 80 of HLA-C is identified as N or K. KIR receptor genotypes are identified as L1
(KIR2DL1), S1 (KIR2DS1, L2 (KIR2DL2) and S2 (KIR2DS2). Absent genotypes for KIR receptors are identified by 00. Columns represent the possible
genotypic combinations for one copy of HLA-C, and the rows indicate the combinations for the second copy. Each cell identifies the theoretical NK cell
responses expected for specific position 80 and KIR genotype combinations found at both HLA-C copies.
KIR, killer immunoglobulin-like receptor; B, balanced; EI, excess inhibition; EA, excess activation; U, undetermined.
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